On February 17, A-Shares continued to rebound, and the growth direction of lithium battery, photovoltaic and other technologies regained its rise. According to the data, as of the press time of February 17, 671 A-share listed companies have been investigated by securities companies since this year. In terms of industry, companies in electronics, medicine, biology, computer and other industries have received intensive attention from securities companies.
three industries are frequently investigated
From the investigation of a single company, the most concerned by securities companies this year is Huadong Medicine Co.Ltd(000963) , which has received 67 securities companies for investigation. As an enterprise dominated by the pharmaceutical industry and expanding the pharmaceutical business and medical beauty industry at the same time, many questions were asked about the company's product R & D and clinical progress, sales promotion, medical beauty business layout and how to look at the future industrial development trend.
Since this year, a total of 671 A-share listed companies have been investigated by securities companies, covering 30 of the 31 Shenwan industries. The listed companies receiving the highest number of research from securities companies also include Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , Zhejiang Sanhua Intelligent Controls Co.Ltd(002050) , Syoung Group Co.Ltd(300740) , Ningbo Ronbay New Energy Technology Co.Ltd(688005) , Winning Health Technology Group Co.Ltd(300253) , Iflytek Co.Ltd(002230) .
Some growth stocks whose share prices continued to fall were not ignored by securities companies due to market performance. For example, since mid December 2021, Qi An Xin Technology Group Inc(688561) -u's share price has continued to decline. On February 17, the intraday share price hit a new low since its listing, and has fallen by more than 23% this year; However, since this year, Qi An Xin Technology Group Inc(688561) -u has received a total of 65 securities companies for research, second only to Huadong Medicine Co.Ltd(000963) . According to the survey minutes, securities companies pay more attention to the causes of the company's losses in 2021 and the strategies to boost rapid growth in 2022.
From the perspective of overall industry distribution, the largest number of Listed Companies in the electronic industry investigated by securities companies this year, up to 87; There are 85 companies in the pharmaceutical and biological industry and 71 companies in the computer industry. In contrast, since this year, securities companies have conducted less research on companies in petroleum and petrochemical, coal, non bank finance and other industries.
In addition, since this year, some listed companies on the Beijing stock exchange have also received the attention of securities companies. As of February 17, Hechang polymerization had received a total of 9 securities companies for research. Data show that the company is committed to expanding the application of modified plastic products in industry through technological progress; Tonghui information, Jinhao medical and Keda automatic control have received at least two securities companies for investigation. From the perspective of the industry, they belong to the computer, pharmaceutical biology and mechanical equipment industries.
the growth sector rebounded strongly
From the perspective of the overall style of the market since this year, the undervalued blue chips have led the rise, while the growth style of science and technology has been significantly suppressed. However, since this week, many growth sectors have rebounded strongly, and their layout value has been further favored by institutions.
According to Zheng Xiaoxia, chief strategic analyst of Huaan Securities Co.Ltd(600909) , the main reason for the continuous weakness of growth style in the early stage is that the continuous strengthening of the expectation of interest rate increase by the Federal Reserve has reduced the risk appetite of US stocks and mapped to the growth style of a shares, while factors such as relatively high valuation and falling prosperity expectation have exacerbated the suppression of the risk appetite of growth style. However, with the significant improvement of these inhibitory factors and the time and space for this round of adjustment of growth style have been basically in place. It is expected that in the future, with the support of factors such as the continuation of the high boom, the maintenance of loose liquidity, and policy support for the development of new energy vehicles and semiconductor industry, the growth style is expected to deduce the market with improved valuation again and make a positive layout at the right time.
For the electronic sector with more frequent research on securities companies, Central China Securities Co.Ltd(601375) analyst Zhu Yushu believes that at present, the performance of various sub sectors in the industry is relatively differentiated. Although there are many hot topics, risk factors such as the Fed's expectation of raising interest rates still exist, and the expectation of tightening risk appetite will have a certain negative impact on the technology sector. From a long-term perspective, under the background of the global epidemic, the demand in 5g, artificial intelligence, Internet of things, new energy vehicles, smart home, remote office, PC and other fields has been directly or indirectly boosted, and the electronic sector has long-term growth momentum.
For the pharmaceutical and biological sector, Huaxi Securities Co.Ltd(002926) analyst Cui Wenliang said that the pharmaceutical outsourcing (CXO) company continued the high-speed growth trend in 2021. Considering that the position of public funds in CXO is still at a high level, it is expected that there will be a differentiated market in 2022, and the target with valuation price ratio and high performance growth will continue to be recommended.
